160 related articles for article (PubMed ID: 24251402)
1. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2014 Feb; 170(2):366-73. PubMed ID: 24251402
[TBL] [Abstract][Full Text] [Related]
2. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
[TBL] [Abstract][Full Text] [Related]
4. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
5. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
6. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
7. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study.
Lee MS; Lin RY; Chang YT; Lai MS
Int J Dermatol; 2012 Dec; 51(12):1454-60. PubMed ID: 23171012
[TBL] [Abstract][Full Text] [Related]
8. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
Abuabara K; Lee H; Kimball AB
Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216
[TBL] [Abstract][Full Text] [Related]
9. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
Kimball AB; Pariser D; Yamauchi PS; Menter A; Teller CF; Shi Y; Yong M; Creamer K; Hooper M; Aras G; Kricorian G; Gelfand JM
J Am Acad Dermatol; 2013 May; 68(5):756-64. PubMed ID: 23357569
[TBL] [Abstract][Full Text] [Related]
10. Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
van Lümig PP; Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):283-91. PubMed ID: 21435026
[TBL] [Abstract][Full Text] [Related]
11. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A; Lebwohl M; Langley RG; Rowland K; Yang YW; Chan D; Miller M; You Y; Yu J; Thaҫi D; Foley P; Papp KA
J Am Acad Dermatol; 2023 Aug; 89(2):274-282. PubMed ID: 37019386
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
[TBL] [Abstract][Full Text] [Related]
14. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.
Chen YJ; Wu CY; Chen TJ; Shen JL; Chu SY; Wang CB; Chang YT
J Am Acad Dermatol; 2011 Jul; 65(1):84-91. PubMed ID: 21458106
[TBL] [Abstract][Full Text] [Related]
15. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs.
Dreiher J; Kresch FS; Comaneshter D; Cohen AD
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1127-32. PubMed ID: 21923837
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: a nationwide cohort study.
Hong JY; Ahn J; Won S; Kim SM; Cho YA; Kim CY; Sung JY; Yu DA; Lee YW; Choe YB
Sci Rep; 2022 Nov; 12(1):20690. PubMed ID: 36450739
[TBL] [Abstract][Full Text] [Related]
17. The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network.
Chiesa Fuxench ZC; Shin DB; Ogdie Beatty A; Gelfand JM
JAMA Dermatol; 2016 Mar; 152(3):282-90. PubMed ID: 26676102
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
19. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
20. The risk of malignancy among biologic-naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database.
Gu Y; Nordstrom BL
J Am Acad Dermatol; 2017 Aug; 77(2):293-301.e1. PubMed ID: 28623045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
